OnKure Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	10.37	4.82	3.9
Research & Development	43.17	32.12	25.86
Operating Expenses	53.54	36.93	29.77
Operating Income	-53.54	-36.93	-29.77
Interest Expense	-0.15	-	-
Interest & Investment Income	2.01	1.62	0.25
Other Non Operating Income (Expenses)	-0.04	-	-
EBT Excluding Unusual Items	-51.71	-35.31	-29.51
Merger & Restructuring Charges	-0.23	-	-
Other Unusual Items	-0.74	-	-
Pretax Income	-52.67	-35.31	-29.51
Net Income	-52.67	-35.31	-29.51
Net Income to Common	-52.67	-35.31	-29.51
Shares Outstanding (Basic)	3	0	-
Shares Outstanding (Diluted)	3	0	-
Shares Change (YoY)	1114.54%	-	-
EPS (Basic)	-15.28	-124.41	-
EPS (Diluted)	-15.28	-124.41	-
Free Cash Flow	-51.17	-34.79	-28.09
Free Cash Flow Per Share	-14.84	-122.59	-
EBITDA	-53.08	-36.52	-29.54
D&A For EBITDA	0.46	0.42	0.23
EBIT	-53.54	-36.93	-29.77

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q